title: [Clinical problems in gemcitabine treatment for unresectable pancreatic cancer in the elderly--a multicentric retrospective study of 53 cases].
abstract: In Gemcitabine treatment, elderly patients with unresectable pancreatic cancer are more likely to suffer from haematological and non-haematological adverse effects than non-elderly patients. Forty percent of the elderly patients were dropped from the initial protocol due to the adverse effects, mainly because of non-haematological events or symptoms. To avoid adverse effects, the administration schedule for Gemcitabine tended to be less often and at a lower dose for elderly patients among members of the Nagano Pancreatic Cancer Study Group. However, the fact that some cases showed a limited effect from this administration schedule albeit without adverse effect, might suggest that the frequency of ordinary administration schedule should be maintained, although the Gemcitabine dose could be decreased in unresectable pancreatic cancer patients in poor condition.
authors.affiliation: Dept of Surgery, Ina Central Hospital.
authors.forename: Nobumichi
authors.initials: N
authors.lastname: Takeuchi
authors.forename: Shinya
authors.initials: S
authors.lastname: Maejima
authors.forename: Osamu
authors.initials: O
authors.lastname: Hasebe
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Matsuda
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Hanazaki
authors.forename: Shoji
authors.initials: S
authors.lastname: Kajikawa
authors.forename: Kenji
authors.initials: K
authors.lastname: Mukawa
authors.forename: Koichi
authors.initials: K
authors.lastname: Hosokawa
authors.forename: Ken
authors.initials: K
authors.lastname: Hayashi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hisa
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Furut
authors.forename: Kazuo
authors.initials: K
authors.lastname: Tajiri
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Fujimori
authors.forename: Gengo
authors.initials: G
authors.lastname: Kaneko
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Ochi
authors.forename: Naoto
authors.initials: N
authors.lastname: Shikama
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Kawa
authors.forename: Shinichi
authors.initials: S
authors.lastname: Miyagawa
authors.forename: Shiro
authors.initials: S
authors.lastname: Miwa
authors.forename: Kendo
authors.initials: K
authors.lastname: Kiyosawa
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine